PulseSight Therapeutics Reports P-I (PST-611-CT1) Trial Data on PST-611 in Dry AMD/Geographic Atrophy

Why It Matters

The data de‑risk PST‑611’s development and signal a potential new therapeutic option for geographic atrophy, an area with no approved treatments, potentially reshaping the dry AMD market. It also illustrates growing European regulatory engagement for U.S. biotech firms.

Key Takeaways

• Phase I tested low/high doses in six late-stage dry AMD patients
• Trial met primary and secondary endpoints with no serious adverse events
• Patients reported vision improvement; one showed reduced GA lesion growth
• CTA filed in France for 20‑patient, 52‑week Phase IIa repeat‑dose study

Pulse Analysis

Dry age‑related macular degeneration (AMD) accounts for the majority of vision loss in people over 60, and geographic atrophy (GA) represents the advanced, irreversible stage with no approved pharmacologic therapy in the United States. Researchers have pursued complement inhibition, neuroprotection, and cell‑based approaches, yet clinical success remains limited. PulseSight’s PST‑611, an intravitreal candidate designed to modulate retinal degeneration pathways, entered the clinic at a time when investors and clinicians are eager for a disease‑modifying solution that could preserve central vision and reduce long‑term care costs.

The Phase I PST‑611‑CT1 trial enrolled six late‑stage GA patients and evaluated two dose levels over a 16‑week period. Safety outcomes were encouraging: no serious adverse events, no intra‑ocular inflammation, and stable best‑corrected visual acuity across the cohort. Importantly, patient‑reported outcomes hinted at subjective visual improvement, and one participant exhibited measurable slowing of lesion expansion beyond the study window—an early efficacy signal that distinguishes PST‑611 from purely safety‑focused early‑stage programs. These findings align with emerging data suggesting that timely retinal intervention can alter disease trajectory.

Following the positive Phase I readout, PulseSight submitted a clinical trial application to France’s ANSM for a 20‑patient, 52‑week Phase IIa repeat‑dose study slated to begin in the second half of 2026, with results anticipated in 2028. Securing European approval early may accelerate a multinational development path and provide a foothold in markets that are actively seeking GA therapies. If the Phase IIa confirms safety and demonstrates statistically significant lesion‑growth reduction, PST‑611 could become a first‑in‑class option, driving substantial market valuation uplift and offering patients a long‑awaited therapeutic avenue.